LPAL2 (Gene)

Entrez:80350

Description:lipoprotein(a) like 2 (pseudogene)

Apolipoprotein(a) is the distinguishing protein moiety of lipoprotein(a), of which elevated plasma levels are correlated with an increased risk of atherosclerosis. This gene is similar to the lipoprotein, Lp(a) gene, but all transcripts produced by this gene contain a truncated open reading frame and are candidates for nonsense-mediated decay. Consequently, this gene is considered to be a pseudogene. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2009]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View LPAL2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with LPAL2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using LPAL2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for LPAL2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with LPAL2.

Results found

Linked to

	Label	Description
	GSE199538 GSE199539 enzalutamide 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE176008 pyridoxine 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE244730 erlotinib PC-9 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE179235 MEK NRAS inhibition 4 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE103567 EZH2 inhibition 5 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212057 SIRT6 overexpression 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE156761 dopamine neuron 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE174745 dopamine neuron 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE144759 FLT3 inhibition 6 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE199538 GSE199539 enzalutamide 2 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE176008 pyridoxine 7 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE244730 erlotinib PC-9 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE179235 MEK NRAS inhibition 4 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE103567 EZH2 inhibition 5 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE212057 SIRT6 overexpression 3 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE156761 dopamine neuron 0 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE174745 dopamine neuron 1 v 4 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 crizotinib 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE144759 FLT3 inhibition 6 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.